ORIGINAL RESEARCH PAPER

Volume - 15 | Issue - 06 | June - 2026 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr

INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH

EMERGING THERAPEUTIC STRATEGIES IN ONCOLOGY: MECHANISTIC ADVANCES AND GLOBAL CLINICAL IMPACT

Oncology

Aditi Munmun Sengupta*

MBBS, MS (Clinical and Bioanalytical Chemistry, United States), Member of Academy of Family Physicians of India, Harvard Medical School Post Graduate Association member*Corresponding Author

ABSTRACT

Background: Oncology therapeutics have undergone a paradigm shift from cytotoxic chemotherapy to targeted and immune-based strategies. **Objective:** To synthesize recent global advances (2024–2026) in emerging oncology therapeutics, focusing on mechanistic innovation and clinical translation.**Methods:** Narrative synthesis of recent clinical trials, regulatory approvals, and global oncology trend reports. Results: Immunotherapy, antibody-drug conjugates (ADCs), and bispecific antibodies dominate current pipelines, with increasing integration of precision medicine and multi-omics.**Conclusion:** Emerging therapies are redefining cancer care through specificity and personalization, though challenges in cost, resistance, and accessibility persist.

KEYWORDS

Oncology, Immunotherapy, Antibody-drug Conjugates, Bispecific Antibodies, Car-t Therapy, Precision Medicine Targeted Therapy

INTRODUCTION

Cancer remains a leading cause of morbidity and mortality globally, with approximately 20 million new cases and 9.7 million deaths annually [Sung et al., 2024)] This substantial and growing burden reflects not only population aging and environmental risk factors but also disparities in access to early detection and effective treatment across regions. Historically, cancer management relied heavily on non-specific cytotoxic chemotherapy and radiotherapy, which, although effective in certain settings, are often associated with significant toxicity and limited selectivity for malignant cells.

Recent years have witnessed a transition from non-specific cytotoxic therapies to precision and immune-mediated approaches, fundamentally altering treatment paradigms. Advances in molecular biology and tumor genomics have enabled the identification of actionable mutations and signaling pathways, facilitating the development of targeted therapies that improve efficacy while minimizing off-target effects. Concurrently, immunotherapy—particularly immune checkpoint inhibitors—has revolutionized oncology by harnessing the host immune system to achieve durable responses in multiple malignancies. In addition, emerging platforms such as antibody-drug conjugates, bispecific antibodies, and cellular therapies are expanding the therapeutic arsenal. Together, these innovations signify a shift toward personalized, mechanism-driven oncology care, with the potential to improve survival outcomes and quality of life across diverse cancer populations.

Evolution of Therapeutic Modalities

The oncology drug development landscape has shifted toward biologically targeted and immune-based interventions, with immunotherapy accounting for nearly 35–40% of current pipelines [IQVIA Institute, 2025]. This transition reflects a deeper understanding of tumor biology, including oncogenic signaling pathways, genomic alterations, and mechanisms of immune evasion. Targeted therapies such as tyrosine kinase inhibitors and monoclonal antibodies are designed to inhibit specific molecular drivers of cancer, resulting in improved therapeutic precision and reduced systemic toxicity compared with conventional chemotherapy. In parallel, immunotherapeutic approaches—particularly immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4—have demonstrated durable clinical responses across a range of solid and hematologic malignancies. Furthermore, newer modalities, including antibody-drug conjugates, bispecific antibodies, and cellular therapies, are increasingly integrated into treatment paradigms. Collectively, these advances underscore a paradigm shift toward mechanism-based, personalized oncology care that prioritizes efficacy, selectivity, and long-term disease control [figure1].

Pie chart illustrating the proportional distribution of major therapeutic classes in the global oncology pipeline. Immunotherapy represents the largest share (38%), followed by targeted therapies (25%), antibody-drug conjugates (12%), bispecific antibodies (10%), cell and gene therapies (8%), and radioligand therapies (7%). The data reflect global development trends emphasizing biologic and precision-based interventions.

Figure 1. Distribution of Oncology Therapeutic Modalities (2025)



Interpretation: Immunotherapy dominates, reflecting sustained clinical efficacy and regulatory momentum.

Immunotherapy and Cellular Engineering

Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 pathways continue to demonstrate durable responses across multiple malignancies [Topalian et al., 2020]. These agents function by releasing inhibitory brakes on T-cell activation, thereby restoring anti-tumor immune surveillance. Clinical application across melanoma, non–small cell lung cancer, renal cell carcinoma, and several other tumor types has shown not only improved overall survival but also the potential for long-term remission in a subset of patients. Combination strategies, such as dual checkpoint blockade or integration with chemotherapy and radiotherapy, have further enhanced response rates, although they are associated with an increased risk of immune-related adverse events. Ongoing research focuses on predictive biomarkers, including PD-L1 expression, tumor mutational burden, and microsatellite instability, to better stratify patients and optimize therapeutic benefit. Meanwhile, CAR-T cell therapy, initially transformative in hematologic cancers, is now expanding into solid tumors through novel antigen targeting and microenvironment modulation strategies [June et al., 2024]. Chimeric antigen receptor T cells are engineered to recognize specific tumor-associated antigens, enabling highly targeted cytotoxicity independent of major histocompatibility complex presentation. While remarkable success has been achieved in B-cell malignancies, translation into solid tumors has been limited by antigen heterogeneity, poor T-cell infiltration, and an immunosuppressive tumor microenvironment. To address these challenges, next-generation CAR-T designs incorporate dual-targeting constructs, armored CARs secreting cytokines, and gene-edited cells with enhanced persistence and resistance to exhaustion. Additionally, strategies combining CAR-T therapy with checkpoint inhibitors or oncolytic viruses are under investigation to improve efficacy. Together, these advances highlight the evolving role of cellular immunotherapy as a cornerstone of next-generation oncology treatment.

PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr

Antibody-Based Therapeutics Expansion

Antibody-Drug Conjugates (ADCs)

ADCs combine monoclonal antibody specificity with cytotoxic payload delivery. As of 2025, over 15 ADCs have received regulatory approval across multiple malignancies [Lambert & Morris, 2025]. Structurally, ADCs consist of three key components: a tumor-targeting monoclonal antibody, a potent cytotoxic agent, and a chemical linker that ensures stability in circulation while enabling controlled payload release within tumor cells. This design allows selective targeting of cancer cells expressing specific antigens, thereby minimizing systemic toxicity compared with conventional chemotherapy. Recent advances in linker technology and payload optimization have significantly improved therapeutic indices, enhancing both efficacy and safety profiles. Clinically, ADCs such as trastuzumab deruxtecan and sacituzumab govitecan have demonstrated substantial improvements in progression-free and overall survival in breast and other solid tumors. Moreover, the expansion of ADCs into earlier lines of therapy and diverse tumor types underscores their growing role as a cornerstone of targeted oncology treatment(figure2).

Bispecific Antibodies

Bispecific T-cell engagers (BiTEs) simultaneously bind tumor antigens and CD3 on T cells, enabling direct cytotoxic activation. Clinical trial activity has increased more than 250% since 2019 (Kaplon et al., 2024). Unlike conventional monoclonal antibodies, bispecific constructs are engineered to recognize two distinct epitopes, facilitating immune synapse formation between T cells and tumor cells. This mechanism promotes rapid and potent tumor cell lysis independent of antigen presentation pathways. Recent innovations include full-length bispecific antibodies with improved half-life, reduced immunogenicity, and enhanced pharmacokinetics compared with earlier BiTE formats. Clinically, bispecific antibodies have shown promising efficacy in hematologic malignancies such as multiple myeloma and lymphoma, with expanding investigations in solid tumors. Challenges remain, including cytokine release syndrome and neurotoxicity; however, step-up dosing regimens and improved molecular designs are mitigating these risks. Collectively, ADCs and bispecific antibodies represent rapidly evolving platforms that are reshaping antibody-based cancer therapeutics through increased precision and immune engagement[figure2].

Figure 2. Growth in ADC and Bispecific Antibody Development (2015–2025)



Figure 2. Growth in Antibody-Drug Conjugate (ADC) and Bispecific Antibody Development (2015–2025).

Line graph depicting the increase in ADC approvals and bispecific antibody clinical trial activity over time. ADC approvals rose from 5 in 2015 to more than 15 by 2025, while bispecific antibody trials expanded markedly from 20 in 2015 to approximately 270 in 2025, reflecting rapid growth in next-generation antibody-based therapeutics.

Interpretation: Rapid expansion highlights these modalities as dominant next-generation platforms

Precision Oncology and Multi-Omics Integration

Advances in genomics, transcriptomics, and spatial biology have enabled tumor-agnostic therapies targeting actionable mutations such as NTRK, RET, and KRAS [Meric-Bernstam et al., 2023]. High-throughput sequencing technologies, including next-generation sequencing (NGS), now allow comprehensive molecular profiling of tumors, facilitating the identification of driver mutations, gene fusions, and pathway alterations that can be therapeutically targeted irrespective of tissue of origin. This paradigm shift has led to the development of tumor-agnostic approvals, exemplified by therapies targeting NTRK fusions and microsatellite instability–high (MSI-H) tumors.

In parallel, transcriptomic and proteomic analyses provide insights into gene expression patterns and functional protein networks, while spatial biology techniques enable the characterization of tumor architecture and immune cell interactions within the tumor microenvironment. Together, these multi-omics approaches offer a more integrated understanding of tumor heterogeneity and disease progression. Artificial intelligence is increasingly used for biomarker discovery and treatment stratification, leveraging large datasets to identify predictive signatures and optimize therapeutic selection. Machine learning models can integrate genomic, clinical, and imaging data to support personalized treatment decisions. As these technologies mature, precision oncology is evolving toward a data-driven, individualized approach that enhances treatment efficacy while minimizing unnecessary toxicity.

Radioligand and Novel Modalities

Radioligand therapy delivers targeted radiation to tumor cells and has shown efficacy in metastatic prostate cancer [Hofman et al., 2021]. This modality utilizes radiolabeled ligands that selectively bind to tumor-specific antigens—such as prostate-specific membrane antigen (PSMA)—allowing localized delivery of cytotoxic radiation while sparing surrounding normal tissues. Clinical studies have demonstrated improved progression-free survival and symptomatic relief in patients with advanced disease, positioning radioligand therapy as an important addition to the therapeutic armamentarium.

Additional emerging strategies are further expanding the scope of oncology therapeutics. Oncolytic viral therapy employs genetically engineered viruses that selectively infect and lyse tumor cells while simultaneously stimulating systemic anti-tumor immune responses. mRNA-based cancer vaccines, building on advances in vaccine technology, are designed to encode tumor-specific neoantigens, thereby eliciting targeted immune activation and immunologic memory. Tumor microenvironment modulation represents another critical approach, aiming to overcome immunosuppressive barriers within the tumor milieu by targeting stromal components, immune checkpoints, and cytokine networks. Together, these innovative strategies highlight a shift toward combinatorial and biologically sophisticated treatments that integrate direct cytotoxicity with immune system engagement to enhance therapeutic efficacy.

Clinical Challenges and Future Directions

Despite rapid innovation, several barriers persist:

Challenge	Description	Strategy
Resistance	Tumor heterogeneity	Combination therapies
Toxicity	Immune-related adverse events	Safer constructs
Cost	High biologic pricing	Biosimilars
Access	Global inequity	Policy reform

Future oncology care will likely involve integrated multimodal regimens, combining immunotherapy, targeted therapy, and precision diagnostics.

The projected expansion of the global oncology therapeutics market from 2024 to 2034, reflects sustained growth driven by innovation in biologic and precision-based therapies [figure3]. The increase from approximately USD 86.2 billion in 2024 to an estimated USD 175.2 billion by 2034 underscores the accelerating adoption of immunotherapies, antibody-drug conjugates, and targeted treatments in clinical practice. This growth trajectory is expected to be further supported by advances in biomarker-driven patient selection, expansion of indications into earlier lines of therapy, and increasing global cancer incidence [IQVIA Institute, 2025]. Additionally, investments in research and development, along with regulatory incentives for breakthrough therapies, are likely to enhance pipeline productivity and market penetration. However, future sustainability will depend on addressing challenges related to treatment affordability, equitable access, and healthcare infrastructure, particularly in low- and middle-income countries. Strategic integration of cost-effective innovations and policy reforms will be essential to ensure broad and sustainable impact.

Figure 3. Global Oncology Therapeutics Market Growth (2024–2034)



Line graph illustrating projected growth in the global oncology therapeutics market from 2024 to 2034. Market size increases from approximately USD 86.2 billion in 2024 to an estimated USD 175.2 billion by 2034, reflecting sustained expansion driven by biologic therapies, precision oncology, and increasing global cancer burden.

Interpretation: Sustained growth reflects increasing adoption of high-cost biologics and precision therapies.

CONCLUSION

Emerging oncology therapeutics are characterized by mechanistic specificity, biomarker-driven selection, and combinatorial strategies. ADCs and bispecific antibodies represent the fastest-growing classes, while CAR-T therapy is expanding into solid tumors. Continued innovation must be balanced with efforts to improve accessibility and affordability. As oncology transitions into an era of precision medicine, the emphasis must shift toward generating robust, reproducible evidence that can be translated across diverse clinical settings. Standardization of biomarker assays, harmonization of clinical trial endpoints, and transparent reporting of real-world outcomes are essential to ensure that therapeutic advances are both reliable and generalizable.

Equally important is the integration of multidisciplinary collaboration, encompassing clinicians, translational scientists, data scientists, and policymakers, to optimize implementation and scalability. Reproducibility in oncology research—through open data sharing, validation cohorts, and adaptive trial designs—will be critical to sustaining scientific credibility and accelerating innovation. From a global health perspective, equitable access to these therapies must remain a central priority, requiring cost-containment strategies, biosimilar development, and policy-level interventions. Ultimately, the success of emerging oncology therapeutics will not be measured solely by technological advancement, but by their ability to deliver consistent, reproducible, and accessible benefits to patients worldwide.

Disclosures

The author declares no conflicts of interest.

Funding

No external funding was received.

REFERENCES

1. Hofman, M. S., et al. (2021). [^177Lu]-PSMA-617 radionuclide treatment in prostate cancer. *The Lancet*, 397(10276), 797–804.
2. IQVIA Institute. (2025). *Global Oncology Trends Report 2025*.
3. June, C. H., et al. (2024). CAR T cell immunotherapy for human cancer. *Science*, 359(6382), 1361–1365.
4. Kaplon, H., et al. (2024). Antibodies to watch in 2024. *mAbs*, 16(1), 229–245.
5. Lambert, J. M., & Morris, C. Q. (2025). Antibody-drug conjugates in cancer therapy. *Molecular Cancer*, 24(1), 45.
6. Meric-Bernstam, F., et al. (2023). Precision oncology: Advances and opportunities. *Nature Reviews Clinical Oncology*, 20(3), 145–159.
7. Sung, H., et al. (2024). Global cancer statistics 2024. *CA: A Cancer Journal for Clinicians*, 74(1), 1–30.
8. Topalian, S. L., et al. (2020). Immune checkpoint blockade: A common denominator approach. *Cancer Cell*, 27(4), 450–461.